Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …

Background Outcomes of treatment of tuberculosis patients with regimens including
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …

Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …

BACKGROUND: Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to
treat than drug-susceptible ones, and threaten global progress towards the targets set by the …

Objective: To compare the effectiveness of second line injectables containing shorter
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …

Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

Background Treatment of multi-drug resistant tuberculosis (MDR-TB) for a prolonged period
with comparatively less effective and more toxic second-line anti-TB drugs is associated with …

Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …